(TNYA) Tenaya Therapeutics - Ratings and Ratios

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing innovative therapies for cardiovascular diseases. Leveraging advanced gene editing, cellular regeneration, and gene addition technologies, the company targets genetically defined heart conditions. Its pipeline includes TN-201, a gene therapy addressing myosin binding protein C3-associated hypertrophic cardiomyopathy, currently in Phase 1 clinical trials. TN-301, a small molecule for heart failure with preserved ejection fraction, is also in Phase 1. Additionally, TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, is in preclinical development. The company is also advancing an adeno-associated virus-based gene therapy delivering the dworf gene for dilated cardiomyopathy and a reprogramming program for heart failure following myocardial infarction. Founded in 2016, Tenaya Therapeutics is based in South San Francisco, California.

Ticker Symbol: TNYA Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Biotechnology

Average Volume 20d: 2913157 Last Price: 0.44 SMA 20: 1.00 SMA 50: 1.22 SMA 200: 2.44 ATR: 0.11

Market Cap: 95.06M USD P/E: 0.00 P/E Forward: 0.00 P/B: 0.84 P/S: 0.00 RoE: None

3-Month Forecast: - Technical Outlook: TNYAs stock price is currently below its 20-day, 50-day, and 200-day moving averages, indicating bearish momentum. The Average True Range (ATR) of 0.11 suggests moderate volatility, with potential price swings of ±$0.04 to ±$0.16 over the next three months. - Fundamental Drivers: The companys pipeline progress, particularly Phase 1 results for TN-201 and TN-301, will be critical drivers. Positive clinical data could trigger upside, while any setbacks may lead to downside. The market capitalization of $95.06M reflects its early-stage clinical status, with a P/B ratio of 0.84 indicating undervaluation relative to book value. - Forecast Range: Based on technical and fundamental factors, TNYAs stock is projected to trade between $0.29 and $0.59 over the next three months. This range accounts for potential catalysts from clinical trials and ongoing macroeconomic conditions.